Home / Health / Migraine Fight: New Guidelines Slash Treatment Threshold
Migraine Fight: New Guidelines Slash Treatment Threshold
25 Sep
Summary
- Migraine prevention now considered for four headache days monthly.
- New guidelines list CGRP inhibitors as first-line treatments.
- Treatment choices now consider cost, side effects, and patient preference.
The American Academy of Neurology has updated its migraine prevention and treatment guidelines, marking a significant shift after nearly 15 years. A key change is the reduced requirement for seeking preventive care, now considering patients with four or more moderate to severe headache days per month, down from the previous eight.
This revision also elevates calcitonin gene-related peptide (CGRP) inhibitors to a first-line defense alongside established migraine medications. These newer treatments target the CGRP protein, which is linked to migraine development.
Patients now have more personalized options, with considerations for cost and side effects alongside symptom severity. Treatment choices encompass daily pills, monthly injections, and quarterly infusions, offering flexibility based on patient preference and lifestyle.
Determining treatment effectiveness typically takes 8-12 weeks for medications and about 24 weeks for Botox. Doctors may utilize headache diaries and in-office assessments to track progress and adjust strategies as needed.
